Get more information on Assisted Reproductive Technology Market - Request Sample Report
The Assisted Reproductive Technology (ART) Market is expected to reach USD 45.75 Bn by 2032 and was valued at USD 27.13 Bn in 2023 the CAGR growth rate will be 5.98% over the forecast period of 2024-2032.
ART refers to medical procedures and strategies used to assist individuals or couples who are experiencing reproductive challenges in achieving pregnancy. These technologies are intended to make conception easier by modifying sperm, eggs, or embryos outside of the body before implanting them in the uterus. There are various types of ART procedures, each of which is meant to address a distinct reproductive issue One of the most prevalent ART techniques is in vitro fertilization (IVF). It entails removing eggs from the ovaries, fertilising them in a laboratory dish with sperm, and then putting the resulting embryo(s) into the uterus. When there are challenges with egg quality, sperm quality, or other fertility issues, IVF is frequently employed.
ART has assisted countless couples and individuals in overcoming infertility and becoming pregnant. However, these treatments can be physically, emotionally, and financially taxing, and success rates can vary depending on factors such as age, underlying health issues, and the quality of the reproductive materials used. Anyone considering ART should speak with a medical practitioner to explore their options and select the best course of action based on their unique circumstances.
ART techniques are designed to address a variety of reproductive difficulties. There are various treatments available to meet individual situations, whether the problem is with the quality of eggs or sperm, fallopian tube blockages, or other reproductive problems.
Drivers
The rising need of overcoming infertility.
The fundamental advantage of ART is that it gives a solution for infertile individuals and couples. It provides a mechanism for conceiving and carrying a pregnancy to term, even when standard approaches have failed.
Restraint
The high cost of the technology
Opportunities
The advancement in the technology
The growth of ART procedures has also led to advances in reproductive biology, genetics, and embryology. These breakthroughs have far-reaching ramifications for medical research and treatment.
Challenges
ART success rates might vary greatly based on factors such as age, underlying health issues, and reproductive material quality. Not every person or couple who undergoes ART will have a successful pregnancy.
Impact of Recession
Economic pressures may cause insurance coverage for fertility treatments to be lowered, making them less accessible to a larger population. Healthcare providers may also reduce their availability of specific services.
During difficult economic times, some individuals and couples may delay or opt not to undertake reproductive treatments, reducing demand for ART services. Impact on Research and Innovation: Recessions can result in lower financing for research and development, thereby slowing the advancement of novel reproductive technologies and therapies.
If the war causes travel restrictions, individuals or couples may find it more difficult to go to specific places for ART treatments, especially if they must cross borders. Travel may be discouraged as a result of safety concerns relating to the conflict.
During times of conflict, healthcare resources may be moved towards immediate medical needs, thereby limiting the availability of medical personnel and facilities for non-emergency treatments such as ART. Geopolitical conflicts can induce emotional stress and psychological suffering in communities that are directly affected by the conflict. Because of its possible impact on hormonal balance and overall health, stress may have an indirect impact on the success rates of ART operations.
By Technology Type
In-Vitro Fertilization (IVF)
Fresh Donor
Frozen Donor
Fresh Non-Donor
Frozen Non-Donor
Artificial Insemination
Intrauterine Insemination
Intracervical Insemination
Intravaginal Insemination
Intratubal Insemination
By End-Use
Fertility Clinics & Other Settings
Hospitals and others
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of Middle East
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
Need any customization research on Assisted Reproductive Technology Market - Enquiry Now
The major players are Vitrolife AB, Merck KGaA, FUJIFILM Irvine Scientific, Ferring B.V., European Sperm Bank, Cosmos Biomedical Ltd., Cryolab Ltd., Bloom IVF Centre, Microm U.K. Ltd., CooperSurgical, Inc. and others.
Regional Analysis
The Assisted Reproductive Technology (ART) market is led by Europe, which held over 36.99% of the revenue share in 2023 this dominance can be attributed to several factors such as rising infertility rates, growing awareness of fertility treatments, advancements in technology, and supportive government initiatives in the region.
North America is projected to see significant growth in the ART market due to positive patient outcomes. Although, Asia Pacific region is also expected to experience a surge in the ART market thanks to ongoing technological advancements and increased research. Japan, for example, witnessed roughly 458,101 ART cycles performed in 2019, resulting in around 60,598 births. This growth is further supported by the high number of registered ART facilities in the country – 624 in total, with 598 reporting some form of ART treatment in 2019.
| Report Attributes | Details |
| Market Size in 2024 | US$ 27.13 Bn |
| Market Size by 2032 | US$ 45.75 Bn |
| CAGR | CAGR of 5.98 % From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments |
By Technology Type [In-Vitro Fertilization (IVF)(Fresh Donor, Frozen Donor, Fresh Non-Donor, Frozen Non-Donor)Artificial Insemination(Intrauterine Insemination, Intracervical Insemination, Intravaginal Insemination, Intratubal Insemination)], By End-Use [Fertility Clinics & other settings, Hospitals and others] |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]). Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia Rest of Latin America) |
| Company Profiles | Cosmos Biomedical, Microm, CooperSurgical, Fujifilm Irvine Scientific, Cryolab, Vitrolife, European Sperm Bank, Bloom IVF Centre, Merck KGaA, Ferring B.V. |
| Key Drivers | • The rising need of overcoming infertility. |
| Market Restraints | • The high cost of the technology |
Ans. The Compound Annual Growth Rate for Assisted Reproductive Technology Market over the forecast period is 5.98%.
Ans. The Assisted Reproductive Technology Market is expected to reach USD 45.75 Bn by 2032 and was valued at USD 27.13 Bn in 2023 the CAGR growth rate will be 5.98% over the forecast period of 2024 -2032.
Ans. The major key players are Vitrolife AB,Merck KGaA, FUJIFILM Irvine Scientific,Ferring B.V., European Sperm Bank, Cosmos Biomedical Ltd.,Cryolab Ltd.,Bloom IVF Centre, Microm U.K. Ltd., CooperSurgical, Inc. and others.
Ans. Europe is the fastest growing region of the Assisted Reproductive Technology Market.
Ans. The rising need of overcoming infertility
Table of Contents
1. Introduction
1.1 Market Definition
1.2 Scope
1.3 Research Assumptions
2. Industry Flowchart
3. Research Methodology
4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
5. Impact Analysis
5.1 Impact Of Russia Ukraine Crisis
5.2 Impact of Economic Slowdown on Major Countries
5.2.1 Introduction
5.2.2 United States
5.2.3 Canada
5.2.4 Germany
5.2.5 France
5.2.6 UK
5.2.7 China
5.2.8 Japan
5.2.9 South Korea
5.2.10 India
6. Value Chain Analysis
7. Porter’s 5 Forces Model
8. Pest Analysis
9. Assisted Reproductive Technology (ART) Market Segmentation, By Technology Type
9.1 Introduction
9.2 Trend Analysis
9.3 In-Vitro Fertilization (IVF)
9.3.1 Fresh Donor
9.3.2 Frozen Donor
9.3.3 Fresh Non-Donor
9.3.4 Frozen Non-Donor
9.4 Artificial Insemination
9.4.1 Intrauterine Insemination
9.4.2 Intracervical Insemination
9.4.3 Intravaginal Insemination
9.4.4 Intratubal Insemination
10. Assisted Reproductive Technology (ART) Market Segmentation, By End-use
10.1 Introduction
10.2 Trend Analysis
10.3 Fertility Clinics & other settings
10.4 Hospitals and others
11. REGIONAL ANALYSIS
11.1 Introduction
11.2 North America
11.2.1 Trend Analysis
11.2.2 North America Assisted Reproductive Technology (ART) Market by Country
11.2.3 North America Assisted Reproductive Technology (ART) Market By Technology Type
11.2.4 North America Assisted Reproductive Technology (ART) Market By End-use
11.2.5 USA
11.2.5.1 USA Assisted Reproductive Technology (ART) Market By Technology Type
11.2.5.2 USA Assisted Reproductive Technology (ART) Market By End-use
11.2.6 Canada
11.2.6.1 Canada Assisted Reproductive Technology (ART) Market By Technology Type
11.2.6.2 Canada Assisted Reproductive Technology (ART) Market By End-use
11.2.7 Mexico
11.2.7.1 Mexico Assisted Reproductive Technology (ART) Market By Technology Type
11.2.7.2 Mexico Assisted Reproductive Technology (ART) Market By End-use
11.3 Europe
11.3.1 Trend Analysis
11.3.2 Eastern Europe
11.3.2.1 Eastern Europe Assisted Reproductive Technology (ART) Market by Country
11.3.2.2 Eastern Europe Assisted Reproductive Technology (ART) Market By Technology Type
11.3.2.3 Eastern Europe Assisted Reproductive Technology (ART) Market By End-use
11.3.2.4 Poland
11.3.2.4.1 Poland Assisted Reproductive Technology (ART) Market By Technology Type
11.3.2.4.2 Poland Assisted Reproductive Technology (ART) Market By End-use
11.3.2.5 Romania
11.3.2.5.1 Romania Assisted Reproductive Technology (ART) Market By Technology Type
11.3.2.5.2 Romania Assisted Reproductive Technology (ART) Market By End-use
11.3.2.6 Hungary
11.3.2.6.1 Hungary Assisted Reproductive Technology (ART) Market By Technology Type
11.3.2.6.2 Hungary Assisted Reproductive Technology (ART) Market By End-use
11.3.2.7 Turkey
11.3.2.7.1 Turkey Assisted Reproductive Technology (ART) Market By Technology Type
11.3.2.7.2 Turkey Assisted Reproductive Technology (ART) Market By End-use
11.3.2.8 Rest of Eastern Europe
11.3.2.8.1 Rest of Eastern Europe Assisted Reproductive Technology (ART) Market By Technology Type
11.3.2.8.2 Rest of Eastern Europe Assisted Reproductive Technology (ART) Market By End-use
11.3.3 Western Europe
11.3.3.1 Western Europe Assisted Reproductive Technology (ART) Market by Country
11.3.3.2 Western Europe Assisted Reproductive Technology (ART) Market By Technology Type
11.3.3.3 Western Europe Assisted Reproductive Technology (ART) Market By End-use
11.3.3.4 Germany
11.3.3.4.1 Germany Assisted Reproductive Technology (ART) Market By Technology Type
11.3.3.4.2 Germany Assisted Reproductive Technology (ART) Market By End-use
11.3.3.5 France
11.3.3.5.1 France Assisted Reproductive Technology (ART) Market By Technology Type
11.3.3.5.2 France Assisted Reproductive Technology (ART) Market By End-use
11.3.3.6 UK
11.3.3.6.1 UK Assisted Reproductive Technology (ART) Market By Technology Type
11.3.3.6.2 UK Assisted Reproductive Technology (ART) Market By End-use
11.3.3.7 Italy
11.3.3.7.1 Italy Assisted Reproductive Technology (ART) Market By Technology Type
11.3.3.7.2 Italy Assisted Reproductive Technology (ART) Market By End-use
11.3.3.8 Spain
11.3.3.8.1 Spain Assisted Reproductive Technology (ART) Market By Technology Type
11.3.3.8.2 Spain Assisted Reproductive Technology (ART) Market By End-use
11.3.3.9 Netherlands
11.3.3.9.1 Netherlands Assisted Reproductive Technology (ART) Market By Technology Type
11.3.3.9.2 Netherlands Assisted Reproductive Technology (ART) Market By End-use
11.3.3.10 Switzerland
11.3.3.10.1 Switzerland Assisted Reproductive Technology (ART) Market By Technology Type
11.3.3.10.2 Switzerland Assisted Reproductive Technology (ART) Market By End-use
11.3.3.11 Austria
11.3.3.11.1 Austria Assisted Reproductive Technology (ART) Market By Technology Type
11.3.3.11.2 Austria Assisted Reproductive Technology (ART) Market By End-use
11.3.3.12 Rest of Western Europe
11.3.3.12.1 Rest of Western Europe Assisted Reproductive Technology (ART) Market By Technology Type
11.3.2.12.2 Rest of Western Europe Assisted Reproductive Technology (ART) Market By End-use
11.4 Asia-Pacific
11.4.1 Trend Analysis
11.4.2 Asia Pacific Assisted Reproductive Technology (ART) Market by Country
11.4.3 Asia Pacific Assisted Reproductive Technology (ART) Market By Technology Type
11.4.4 Asia Pacific Assisted Reproductive Technology (ART) Market By End-use
11.4.5 China
11.4.5.1 China Assisted Reproductive Technology (ART) Market By Technology Type
11.4.5.2 China Assisted Reproductive Technology (ART) Market By End-use
11.4.6 India
11.4.6.1 India Assisted Reproductive Technology (ART) Market By Technology Type
11.4.6.2 India Assisted Reproductive Technology (ART) Market By End-use
11.4.7 Japan
11.4.7.1 Japan Assisted Reproductive Technology (ART) Market By Technology Type
11.4.7.2 Japan Assisted Reproductive Technology (ART) Market By End-use
11.4.8 South Korea
11.4.8.1 South Korea Assisted Reproductive Technology (ART) Market By Technology Type
11.4.8.2 South Korea Assisted Reproductive Technology (ART) Market By End-use
11.4.9 Vietnam
11.4.9.1 Vietnam Assisted Reproductive Technology (ART) Market By Technology Type
11.4.9.2 Vietnam Assisted Reproductive Technology (ART) Market By End-use
11.4.10 Singapore
11.4.10.1 Singapore Assisted Reproductive Technology (ART) Market By Technology Type
11.4.10.2 Singapore Assisted Reproductive Technology (ART) Market By End-use
11.4.11 Australia
11.4.11.1 Australia Assisted Reproductive Technology (ART)Market By Technology Type
11.4.11.2 Australia Assisted Reproductive Technology (ART)Market By End-use
11.4.12 Rest of Asia-Pacific
11.4.12.1 Rest of Asia-Pacific Assisted Reproductive Technology (ART)Market By Technology Type
11.4.12.2 Rest of Asia-Pacific Assisted Reproductive Technology (ART)Market By End-use
11.5 Middle East & Africa
11.5.1 Trend Analysis
11.5.2 Middle East
11.5.2.1 Middle East Assisted Reproductive Technology (ART)Market by Country
11.5.2.2 Middle East Assisted Reproductive Technology (ART)Market By Technology Type
11.5.2.3 Middle East Assisted Reproductive Technology (ART)Market By End-use
11.5.2.4 UAE
11.5.2.4.1 UAE Assisted Reproductive Technology (ART)Market By Technology Type
11.5.2.4.2 UAE Assisted Reproductive Technology (ART)Market By End-use
11.5.2.5 Egypt
11.5.2.5.1 Egypt Assisted Reproductive Technology (ART)Market By Technology Type
11.5.2.5.2 Egypt Assisted Reproductive Technology (ART)Market By End-use
11.5.2.5 South Africa
11.5.2.5.1 South Africa Assisted Reproductive Technology (ART)Market By Technology Type
11.5.2.5.2 South Africa Assisted Reproductive Technology (ART)Market By End-use
11.5.2.6 Rest of Africa
11.5.2.6.1 Rest of Africa Assisted Reproductive Technology (ART)Market By Technology Type
11.5.2.6.2 Rest of Africa Assisted Reproductive Technology (ART)Market By End-use
11.5.2.6 Saudi Arabia
11.5.2.6.1 Saudi Arabia Assisted Reproductive Technology (ART)Market By Technology Type
11.5.2.6.2 Saudi Arabia Assisted Reproductive Technology (ART)Market By End-use
11.5.2.7 Qatar
11.5.2.7.1 Qatar Assisted Reproductive Technology (ART)Market By Technology Type
11.5.2.7.2 Qatar Assisted Reproductive Technology (ART)Market By End-use
11.5.2.8 Rest of Middle East
11.5.2.8.1 Rest of Middle East Assisted Reproductive Technology (ART)Market By Technology Type
11.5.2.8.2 Rest of Middle East Assisted Reproductive Technology (ART)Market By End-use
11.5.3 Africa
11.5.3.1 Africa Assisted Reproductive Technology (ART)Market by Country
11.5.3.2 Africa Assisted Reproductive Technology (ART)Market By Technology Type
11.5.3.3 Africa Assisted Reproductive Technology (ART)Market By End-use
11.6 Latin America
11.6.1 Trend Analysis
11.6.2 Latin America Assisted Reproductive Technology (ART)Market by Country
11.6.3 Latin America Assisted Reproductive Technology (ART)Market By Technology Type
11.6.4 Latin America Assisted Reproductive Technology (ART)Market By End-use
11.6.5 Brazil
11.6.5.1 Brazil Assisted Reproductive Technology (ART)Market By Technology Type
11.6.5.2 Brazil Assisted Reproductive Technology (ART)Market By End-use
11.6.6 Argentina
11.6.6.1 Argentina Assisted Reproductive Technology (ART)Market By Technology Type
11.6.6.2 Argentina Assisted Reproductive Technology (ART)Market By End-use
11.6.7 Colombia
11.6.7.1 Colombia Assisted Reproductive Technology (ART)Market By Technology Type
11.6.7.2 Colombia Assisted Reproductive Technology (ART)Market By End-use
11.6.8 Rest of Latin America
11.6.8.1 Rest of Latin America Assisted Reproductive Technology (ART)Market By Technology Type
11.6.8.2 Rest of Latin America Assisted Reproductive Technology (ART)Market By End-use
12. Company Profiles
12.1 Vitrolife AB
12.1.1 Company Overview
12.1.2 Financial
12.1.3 Technology Types/ Services Offered
12.1.4 SWOT Analysis
12.1.5 The SNS View
12.2 Merck KGaA
12.2.1 Company Overview
12.2.2 Financial
12.2.3 Technology Types/ Services Offered
12.2.4 SWOT Analysis
12.2.5 The SNS View
12.3 FUJIFILM Irvine Scientific
12.3.1 Company Overview
12.3.2 Financial
12.3.3 Technology Types/ Services Offered
12.3.4 SWOT Analysis
12.3.5 The SNS View
12.4 Ferring B.V.
12.4.1 Company Overview
12.4.2 Financial
12.4.3 Technology Types/ Services Offered
12.4.4 SWOT Analysis
12.4.5 The SNS View
12.5 European Sperm Bank
12.5.1 Company Overview
12.5.2 Financial
12.5.3 Technology Types/ Services Offered
12.5.4 SWOT Analysis
12.5.5 The SNS View
12.6 Cosmos Biomedical Ltd.
12.6.1 Company Overview
12.6.2 Financial
12.6.3 Technology Types/ Services Offered
12.6.4 SWOT Analysis
12.6.5 The SNS View
12.7 Cryolab Ltd.
12.7.1 Company Overview
12.7.2 Financial
12.7.3 Technology Types/ Services Offered
12.7.4 SWOT Analysis
12.7.5 The SNS View
13. Competitive Landscape
13.1 Competitive Benchmarking
13.2 Market Share Analysis
13.3 Recent Developments
13.3.1 Industry News
13.3.2 Company News
13.3.3 Mergers & Acquisitions
14. USE Cases and Best Practices
15. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
DNA Synthesis Market was valued at USD 3.59 billion in 2023 and is expected to reach USD 15.48 billion by 2032, growing at a CAGR of 17.66% from 2024 to 2032.
The Smart Fertility Tracker Market was valued at USD 0.17 billion in 2023, and is expected to reach USD 0.42 billion by 2032, and grow at a CAGR of 10.59% over the forecast period 2024-2032.
The Digital PCR Market size was valued at USD 6.77 billion in 2023 & projected to reach USD 14.89 billion by 2032, at a CAGR of 9.16% by 2024-2032.
The Preeclampsia Diagnostics Market size was valued at USD 1.08 Billion in 2023 and is expected to reach USD 1.33 Billion By 2031 with a growing CAGR of 2.7% over the forecast period of 2024-2031.
The Healthcare Virtual Assistants Market size was USD 1290.85 million in 2023 and will reach USD 14073.35 billion with a growing CAGR of 34.8% by 2024-2031.
The global antibiotics market size was USD 47.23 Billion in 2023 & is expected to reach USD 65.23 billion by 2032 at a CAGR of 3.70%.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
